Compare StocksABBV vs AEE

AbbVie Inc. (ABBV) vs Ameren Corporation (AEE): Which Is the Better Buy in 2026?

As of 2026-08-03, ABBV is overvalued at $251, with a DCF intrinsic value of $178 and a margin of safety of -41%. AEE is overvalued at $110, with an intrinsic value of $0 and a margin of safety of -100%. Of the two, ABBV has the wider margin of safety.

ABBV
AbbVie Inc.
$250.94
VS
AEE
Ameren Corporation
$109.61

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
AEE

    Risks

    ABBV
    • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
    • Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
    AEE
    • PEG ratio of 2.45 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
    • High leverage (1.58x net debt/equity) combined with thin interest coverage (-1.0x) poses financial risk.
    • Net debt/EBITDA of 5.5x indicates heavy leverage — it would take over 4 years of EBITDA to pay off net debt.

    Key Valuation Metrics

    Learn more →
    ABBV
    AEE
    Valuation
    N/A
    Free Cash Flow
    $-1.77B
    N/A
    FCF Yield
    N/A
    70.89
    Trailing P/E
    19.30
    15.41
    Forward P/E
    18.87
    Quality & Moat
    27.60%
    ROIC
    4.10%
    N/A
    ROE
    11.94%
    72.79%
    Gross Margin
    52.35%
    0.41
    PEG Ratio
    2.45
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    1.58
    N/A
    Interest Coverage
    N/A
    2.06
    Net Debt / EBITDA
    5.53
    2.76%
    Dividend Yield
    2.74%
    ABBV: 5Ties: 2AEE: 1
    ABBVAEE

    Historical Fundamentals

    Learn more →
    ABBV

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    AEE

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    ABBV
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-19.85B
    Δ Market Cap
    +$118.02B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    AEE
    Not enough historical data to compute the retained earnings test.

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    ABBV
    40.7% Overvalued
    Price is 40.7% above estimated fair value
    Current Price: $250.94
    Fair Value: $178.31
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    AEE
    Insufficient Data
    Enter initial FCF to calculate intrinsic value
    Current Price: $109.61
    Fair Value: $0.00
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    ABBV

    Requires positive FCF to compute implied growth rate.

    AEE

    Requires positive FCF to compute implied growth rate.

    Economic Moat Score

    Learn more →
    ABBV
    82/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    AEE
    39/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable moat detected, though margin stability shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    ABBV
    -2.86
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    AEE

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    ABBV
    Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
    No. of Institutional Holders5,146
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    AEE
    Insiders 0.3%Institutions 86.4%Retail & Other 13.2%
    No. of Institutional Holders1,242
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    ABBV
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    AEE
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    ABBV
    0
    Sells (3M)
    0
    Sells (12M)
    No open market insider sales found.
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    AEE
    1
    Sells (3M)
    18
    Sells (12M)
    Total value (12M): $7.91M
    SHAW THERESA A
    Officer
    $199,476
    @ $109.30 · 2026-05-14
    MOEHN MICHAEL L
    Officer
    $738,595
    @ $113.63 · 2026-05-01
    LINDGREN MARK C
    Officer of Subsidiary Company
    $231,844
    @ $111.84 · 2026-03-03
    SCHUKAR SHAWN E
    Officer of Subsidiary Company
    $556,404
    @ $111.84 · 2026-03-03
    LYONS MARTIN J JR
    Chief Executive Officer
    $3.00M
    @ $111.84 · 2026-03-03
    FLORES RAFAEL
    Director
    $178,432
    @ $111.52 · 2026-02-17
    MIZELL GWENDOLYN G.
    Officer of Subsidiary Company
    $393,473
    @ $110.90 · 2026-02-17
    SHAW THERESA A
    Officer
    $36,364
    @ $111.89 · 2026-02-17
    MOEHN MICHAEL L
    Officer
    $673,400
    @ $103.60 · 2026-02-02
    FLORES RAFAEL
    Director
    $23,672
    @ $105.21 · 2025-11-17
    FLORES RAFAEL
    Director
    $65,930
    @ $105.32 · 2025-11-17
    HARSHMAN RICHARD J
    Director
    $262,250
    @ $104.90 · 2025-11-14
    SHAW THERESA A
    Officer
    $34,050
    @ $104.77 · 2025-11-14
    SMITH PATRICK E.
    Officer
    $251,939
    @ $104.80 · 2025-11-14
    MOEHN MICHAEL L
    Chief Financial Officer
    $659,360
    @ $101.44 · 2025-11-03
    LINDGREN MARK C
    Officer of Subsidiary Company
    $353,115
    @ $100.89 · 2025-09-12
    MIZELL GWENDOLYN G.
    Officer of Subsidiary Company
    $149,250
    @ $99.50 · 2025-09-03
    MIZELL GWENDOLYN G.
    Officer of Subsidiary Company
    $101,790
    @ $101.79 · 2025-08-22
    MOEHN MICHAEL L
    Chief Financial Officer
    $666,510
    @ $102.54 · 2025-08-01
    MOEHN MICHAEL L
    Chief Financial Officer
    $641,030
    @ $98.62 · 2025-05-20
    LINDGREN MARK C
    Officer of Subsidiary Company
    $194,087
    @ $103.79 · 2025-03-04
    NWAMU CHONDA J.
    Officer
    $557,535
    @ $101.37 · 2025-03-04
    SCHUKAR SHAWN E
    Officer of Subsidiary Company
    $492,276
    @ $103.79 · 2025-03-04
    LYONS MARTIN J JR
    Chief Executive Officer
    $1.54M
    @ $103.79 · 2025-03-04
    SHAW THERESA A
    Officer
    $99,530
    @ $99.53 · 2025-02-26
    MOEHN MICHAEL L
    Chief Financial Officer
    $634,010
    @ $97.54 · 2025-02-20
    FLORES RAFAEL
    Director
    $186,067
    @ $97.93 · 2025-02-19
    IVEY CRAIG S
    Director
    $266,901
    @ $98.27 · 2025-02-19
    MOEHN MICHAEL L
    Chief Financial Officer
    $598,975
    @ $92.15 · 2024-11-20
    NWAMU CHONDA J.
    General Counsel
    $131,923
    @ $81.94 · 2024-08-28
    MOEHN MICHAEL L
    Chief Financial Officer
    $536,445
    @ $82.53 · 2024-08-20
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    ABBV
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    AEE
    FearGreed
    😐Neutral(52/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    ABBV
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    AEE
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (52)
    View ABBV Full AnalysisView AEE Full Analysis

    Frequently Asked Questions: ABBV vs AEE

    Is AbbVie Inc. or Ameren Corporation more undervalued in 2026?

    Based on our discounted cash flow model, ABBV trades at a -40.7% margin of safety (intrinsic value $178 vs. price $251), compared to AEE's -100.0% margin of safety (intrinsic $0 vs. $110).

    Which stock has a wider economic moat, AbbVie Inc. or Ameren Corporation?

    ABBV scores 82/100 (Wide moat), while AEE scores 39/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Ameren Corporation in financial distress?

    AEE's Altman Z-Score of 0.4 places it in the Distress zone, signaling elevated bankruptcy risk. ABBV scores 2.4 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which stock has higher return on invested capital, AbbVie Inc. or Ameren Corporation?

    ABBV earns 27.6% ROIC versus AEE's 4.1%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, AbbVie Inc.'s or Ameren Corporation's?

    AEE's dividend earns a safety score of 59/100 (Borderline), compared to ABBV's 39/100 (Unsafe). AEE has raised its dividend for 3 consecutive years.